These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 30810454)

  • 41. A linear model method for rank measures of association from longitudinal studies with fixed conditions (visits) for data collection and more than two groups.
    Jung JW; Koch GG
    J Biopharm Stat; 1998 May; 8(2):299-316. PubMed ID: 9598424
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A Dirichlet process mixture model for clustering longitudinal gene expression data.
    Sun J; Herazo-Maya JD; Kaminski N; Zhao H; Warren JL
    Stat Med; 2017 Sep; 36(22):3495-3506. PubMed ID: 28620908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnosing model diagnostics.
    Karlsson MO; Savic RM
    Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Some conceptual and statistical issues in analysis of longitudinal psychiatric data. Application to the NIMH treatment of Depression Collaborative Research Program dataset.
    Gibbons RD; Hedeker D; Elkin I; Waternaux C; Kraemer HC; Greenhouse JB; Shea MT; Imber SD; Sotsky SM; Watkins JT
    Arch Gen Psychiatry; 1993 Sep; 50(9):739-50. PubMed ID: 8357299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Blinded sample size recalculation for clinical trials with normal data and baseline adjusted analysis.
    Friede T; Kieser M
    Pharm Stat; 2011; 10(1):8-13. PubMed ID: 19943322
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline observation carry forward: reasoning, properties, and practical issues.
    Shao J; Jordan DC; Pritchett YL
    J Biopharm Stat; 2009 Jul; 19(4):672-84. PubMed ID: 20183433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Statistical considerations on design and analysis of bridging and multiregional clinical trials.
    Tsong Y
    J Biopharm Stat; 2012 Sep; 22(5):1078-80. PubMed ID: 22946952
    [No Abstract]   [Full Text] [Related]  

  • 48. Sample size calculations with multiplicity adjustment for longitudinal clinical trials with missing data.
    Lu K
    Stat Med; 2012 Jan; 31(1):19-28. PubMed ID: 22162151
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Power analyses for negative binomial models with application to multiple sclerosis clinical trials.
    Rettiganti M; Nagaraja HN
    J Biopharm Stat; 2012; 22(2):237-59. PubMed ID: 22251172
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Alternative approaches to the analysis of binary and categorical repeated measurements.
    Kenward MG; Jones B
    J Biopharm Stat; 1992; 2(2):137-70. PubMed ID: 1300210
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MMRM versus MI in dealing with missing data--a comparison based on 25 NDA data sets.
    Siddiqui O
    J Biopharm Stat; 2011 May; 21(3):423-36. PubMed ID: 21442517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Subgroup analysis with semiparametric models toward precision medicine.
    Yuan A; Chen X; Zhou Y; Tan MT
    Stat Med; 2018 May; 37(11):1830-1845. PubMed ID: 29575056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Dental Implant Clinical Research Group study: study design and statistical methods utilized.
    Ochi S
    Ann Periodontol; 2000 Dec; 5(1):12-4. PubMed ID: 11885171
    [No Abstract]   [Full Text] [Related]  

  • 54. Test Statistics and Confidence Intervals to Establish Noninferiority between Treatments with Ordinal Categorical Data.
    Zhang F; Miyaoka E; Huang F; Tanaka Y
    J Biopharm Stat; 2015; 25(5):921-38. PubMed ID: 24919157
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adaptive group sequential test with changing patient population.
    Feng H; Liu Q
    J Biopharm Stat; 2012; 22(4):662-78. PubMed ID: 22651107
    [TBL] [Abstract][Full Text] [Related]  

  • 56. On two-sample McNemar test.
    Xiang JX
    J Biopharm Stat; 2016; 26(2):217-26. PubMed ID: 25629432
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Clinical trials simulation: a statistical approach.
    Westfall PH; Tsai K; Ogenstad S; Tomoiaga A; Moseley S; Lu Y
    J Biopharm Stat; 2008; 18(4):611-30. PubMed ID: 18607794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of data analysis strategies for intent-to-treat analysis in pre-test-post-test designs with substantial dropout rates.
    Salim A; Mackinnon A; Christensen H; Griffiths K
    Psychiatry Res; 2008 Sep; 160(3):335-45. PubMed ID: 18718673
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and evaluation of multiregional trials with heterogeneous treatment effect across regions.
    Chen CT; Hung HM; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1037-50. PubMed ID: 22946948
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multilevel functional clustering analysis.
    Serban N; Jiang H
    Biometrics; 2012 Sep; 68(3):805-14. PubMed ID: 22313290
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.